Almirall SA : Q3 earnings preview. SG&A accelerates on Lebrikizumab
>Sales to keep the modest growth pace seen in H1 2023 while margins contract as Lebri’s launch costs ramp up - The company is due to publish its Q3 2023 results on 9 November before the market opens. We expect total sales to grow 2% y-o-y to € 204m (vs +8% in Q2 and +2% in Q1), while the absolute figure is 11-12% below the Q1 and Q2 due to the usual seasonality yet a touch above. At the EBITDA level, we expect a decline of -11% to € 35m, explained by the ramp-up in la...Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.